Ultragenyx Pharmaceutical (RARE) Accumulated Depreciation & Amortization: 2016-2024
- Ultragenyx Pharmaceutical's Accumulated Depreciation & Amortization rose 34.87% to $112.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $309.3 million, marking a year-over-year increase of 32.06%. This contributed to the annual value of $112.5 million for FY2024, which is 34.87% up from last year.
- According to the latest figures from Q4 2024, Ultragenyx Pharmaceutical's Accumulated Depreciation & Amortization is $112.5 million, which was up 34.87% from $83.4 million recorded in Q4 2023.
- Ultragenyx Pharmaceutical's 5-year Accumulated Depreciation & Amortization high stood at $112.5 million for Q4 2024, and its period low was $37.4 million during Q4 2020.
- For the 3-year period, Ultragenyx Pharmaceutical's Accumulated Depreciation & Amortization averaged around $86.4 million, with its median value being $83.4 million (2023).
- Data for Ultragenyx Pharmaceutical's Accumulated Depreciation & Amortization shows a peak YoY soared of 43.88% (in 2020) over the last 5 years.
- Quarterly analysis of 5 years shows Ultragenyx Pharmaceutical's Accumulated Depreciation & Amortization stood at $37.4 million in 2020, then soared by 33.82% to $50.0 million in 2021, then climbed by 26.67% to $63.4 million in 2022, then spiked by 31.59% to $83.4 million in 2023, then surged by 34.87% to $112.5 million in 2024.
- Its Accumulated Depreciation & Amortization stands at $112.5 million for Q4 2024, versus $83.4 million for Q4 2023 and $63.4 million for Q4 2022.
